FEASTNCT07898839
FEAST and HOPE: Redox PSC Pilot Study
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (4)
Arms and interventions
Single-arm, open-label. All participants follow a study diet and take four oral agents targeting disulfidptosis for approximately 16 weeks (Baseline through Week 16). Study diet: guided by study dietitians, with grocery support and meal photo logging via the MetaBite app. Study agents: alpha-lipoic acid (ALA) 600 mg once daily in Week 0, then 600 mg twice daily from Week 1; N-acetylcysteine (NAC); nicotinamide riboside (NR) 500 mg twice daily; and metformin extended-release, with doses titrated over the initial weeks per protocol. Enrollment is stratified by inflammatory bowel disease (IBD) status. Study agents may be withdrawn sequentially per the protocol-defined ALP management plan.
Dietary supplements: N-Acetyl Cysteine (NAC), Alpha-Lipoic Acid (ALA), Nicotinamide Riboside (NR)
Drugs: Metformin Hydrochloride Extended-Release Tablets
Other: Study Diet